ENXTPA:SANPharmaceuticals
Sanofi’s Dynavax Deal Puts Hepatitis B Vaccine At Center Stage
Sanofi (ENXTPA:SAN) has agreed to acquire Dynavax Technologies, adding a marketed hepatitis B vaccine to its portfolio.
The deal expands Sanofi's vaccines business and adds an approved asset in the immunology segment.
For you as an investor, this move sits squarely in Sanofi's core line of business as a global vaccines and immunology company. The addition of a commercial hepatitis B vaccine fits with long running demand for adult and high risk population immunization, an area where large...